Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baminercept in active RA with inadequate response to anti-TNF
NCT00458861Phase 2Terminated
- Sponsor
- Biogen
- Start
- Mar 2007
- Primary completion
- Oct 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing BG9924 + MTX with Placebo + MTX (2 arms). Primary endpoint: Evaluate efficacy of BG9924 in combination with methotrexate at 26 weeks. Started Mar 2007; status: terminated.
02
Drugs
baminercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00458861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458861.